Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study

BACKGROUND: rVIII‐SingleChain is a recombinant single‐chain factor VIII used to treat people with hemophilia A. OBJECTIVES: The aim of this extension study was to investigate the long‐term safety and efficacy of rVIII‐SingleChain prophylaxis in ≥200 previously treated patients (PTPs) with hemophilia...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlangu, Johnny, Abdul Karim, Faraizah, Stasyshyn, Oleksandra, Korczowski, Bartosz, Salazar, Blanca, Lucas, Samantha, Suen, Amy, Goldstein, Brahm, Chung, Thomas, Pabinger, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844480/
https://www.ncbi.nlm.nih.gov/pubmed/35224416
http://dx.doi.org/10.1002/rth2.12665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844480/
https://www.ncbi.nlm.nih.gov/pubmed/35224416
http://dx.doi.org/10.1002/rth2.12665

Ejemplares similares